|
1
|
TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells.
|
Cell Cycle
|
2011
|
2.41
|
|
2
|
Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.
|
Clin Cancer Res
|
2008
|
1.18
|
|
3
|
Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin.
|
J Biol Chem
|
2010
|
1.16
|
|
4
|
Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion.
|
Cancer Res
|
2012
|
1.11
|
|
5
|
Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.
|
Oncotarget
|
2010
|
1.07
|
|
6
|
Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
|
Clin Cancer Res
|
2006
|
1.04
|
|
7
|
Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
|
Clin Cancer Res
|
2008
|
1.03
|
|
8
|
Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.
|
Int J Cancer
|
2009
|
0.95
|
|
9
|
Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility.
|
Mol Cancer
|
2009
|
0.95
|
|
10
|
Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms.
|
J Biol Chem
|
2002
|
0.94
|
|
11
|
c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
|
Int J Cancer
|
2003
|
0.94
|
|
12
|
Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation.
|
Cell Cycle
|
2013
|
0.93
|
|
13
|
Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma.
|
Clin Cancer Res
|
2008
|
0.92
|
|
14
|
The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.
|
Neoplasia
|
2012
|
0.85
|
|
15
|
Activation of p53-dependent responses in tumor cells treated with a PARC-interacting peptide.
|
Biochem Biophys Res Commun
|
2008
|
0.82
|
|
16
|
Insulin-like growth factor binding protein 5: contribution to growth and differentiation of neuroblastoma cells.
|
Ann N Y Acad Sci
|
2004
|
0.79
|
|
17
|
C/EBP alpha and beta mimic retinoic acid activation of IGFBP-5 in neuroblastoma cells by a mechanism independent from binding to their site.
|
Exp Cell Res
|
2005
|
0.79
|
|
18
|
Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
|
Clin Cancer Res
|
2005
|
0.76
|
|
19
|
Bim-dependent apoptosis follows IGFBP-5 down-regulation in neuroblastoma cells.
|
Biochem Biophys Res Commun
|
2006
|
0.76
|
|
20
|
Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
|
Int J Cancer
|
2007
|
0.76
|